Health-care companies fell amid intensifying competition in the obesity-drug niche.
Shares of Structure Therapeutics soared after the biotechnology firm said patients on its weight-loss pill aleniglipron had lost 14.2% of their body weight over 36 weeks, while patients on a placebo gained 1%.
Shares of WAVE Life Sciences more than doubled after its weight-loss injection showed promise.
Shares of obesity-drug makers Novo Nordisk and Eli Lilly fell amid competition concerns.
Drug makers such as Novo, Lilly and Pfizer are moving to sell their medicines directly to patients, abandoning drug wholesalers and other middlemen they have long relied on, The Wall Street Journal reported.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
12-08-25 1749ET
